Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.43 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | WIZ | O95785 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30122031 | 1.00 | CRBN (0.51) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL24742723 | 0.88 | CRBN (0.54) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL30122023 | 0.88 | CRBN (0.54) | CRBNIKZF2IKZF1DDB1CSNK1A1 | |
| SCHEMBL25010545 | 0.85 | CRBN (0.60) | CRBNIKZF2IKZF1DDB1 | |
| SCHEMBL24745412 | 0.84 | CRBN (0.47) | CRBNIKZF1DDB1CSNK1A1 | |
| SCHEMBL30121824 | 0.84 | CRBN (0.47) | CRBNIKZF1DDB1CSNK1A1 | |
| SCHEMBL31201836 | 0.84 | CRBN (0.59) | CRBNGSPT1WIZ | |
| SCHEMBL30919850 | 0.84 | CRBN (0.58) | CRBNIKZF2DDB1CSNK1A1GSPT1 | |
| SCHEMBL24744841 | 0.84 | CRBN (0.58) | CRBNIKZF2DDB1CSNK1A1GSPT1 | |
| SCHEMBL29223713 | 0.84 | CRBN (0.59) | CRBNGSPT1WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |